A5059929672- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Immunotherapy and Biomarkers
- Global Cancer Incidence and Screening
- Health Systems, Economic Evaluations, Quality of Life
- Gastric Cancer Management and Outcomes
- Economic and Financial Impacts of Cancer
- Esophageal Cancer Research and Treatment
- Medical Imaging Techniques and Applications
- Brain Metastases and Treatment
- Healthcare Policy and Management
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Pancreatic and Hepatic Oncology Research
- Respiratory Support and Mechanisms
- Cancer therapeutics and mechanisms
- Colorectal Cancer Screening and Detection
- Colorectal and Anal Carcinomas
- Air Quality and Health Impacts
- Frailty in Older Adults
- Schizophrenia research and treatment
- Asthma and respiratory diseases
National Cheng Kung University Hospital
2015-2025
Yale University
2021-2025
National Taiwan University
2023
National Taiwan University Hospital
2023
Institute of Biomedical Sciences, Academia Sinica
2023
National Cheng Kung University
2011-2023
Bridge University
2023
Udayana University
2021
Dharmais Cancer Hospital
2021
Teikyo University Hospital
2021
BackgroundA screening program for lung cancer requires more empirical evidence. Based on the experience of National Lung Screening Trial (NLST), we developed a method to adjust lead-time bias and quality-of-life changes estimating cost-effectiveness implementing computed tomography (CT) in Taiwan.MethodsThe target population was high-risk (≥30 pack-years) smokers between 55 75 years age. From nation-wide, 13-year follow-up cohort, estimated quality-adjusted life expectancy (QALE),...
Brain metastases (BM) are common in advanced non-small cell lung cancer (NSCLC), and the prognosis is poor with few therapeutic options. This study evaluated efficacy of three epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) preventing treating BM patients EGFR mutation-positive NSCLC.Patients NSCLC who visited a tertiary referral center from 1 December 2013 to 30 November 2017 were analyzed retrospectively. They received gefitinib, erlotinib, or afatinib until disease...
Previous studies have demonstrated the association between EGFR mutations and distant metastasis. However, for subsequent brain metastasis (BM) in stages I-III non-small cell lung cancer (NSCLC) patients remains inconclusive. We conducted a retrospective analysis to clarify impact of on incidence BM associated survival with stage NSCLC. A total 491 screened were retrospectively enrolled. Brain MRI or CT was used detect BM. Cumulative overall (OS) after diagnosis estimated by Kaplan-Meier...
The study examined whether the items of World Health Organization Quality Life-Brief questionnaire can assess its four underlying domains (Physical, Psychological, Social, and Environment) in a sample lung cancer patients. All patients ( n = 1150) were recruited from medical center Tainan, each participant completed Life-Brief. Several Rasch rating scale models used to examine data-model fit, analyses corroborated that domain could be unidimensional. Although three found have poor all other...
Background: Lazertinib demonstrates efficacy similar to that of osimertinib in the first-line treatment epidermal growth factor receptor ( EGFR)-mutated advanced lung cancer. However, its cost-effectiveness has not yet been evaluated. Objective: To study lazertinib as a for patients with EGFR-mutated Design: A partitioned survival model-based analysis. Methods: We conducted economic analysis from perspective healthcare sector lifetime horizon. Simulated were entered into models upon...
Introduction Comparison of the effectiveness and cost-effectiveness three first-line EGFR-tyrosine kinase inhibitors (TKIs) would improve patients' clinical benefits save costs. Using real-world data, this study attempted to directly compare afatinib, erlotinib, gefitinib. Methods During May 2011-December 2017, all patients with non-small cell lung cancer (NSCLC) visiting a tertiary center were invited fill out EuroQol five-dimension (EQ-5D) questionnaires World Health Organization Quality...
Researchers have not simultaneously compared the cost-effectiveness of six immunotherapies with chemotherapy for advanced non-small cell lung cancer. This study evaluated across different programmed death-ligand 1 (PD-L1) levels.A Markov model lifetime horizon was created seven regimens: pembrolizumab plus (pembro-chemo), nivolumab ipilimumab (nivo-ipi), nivolumab, (nivo-ipi-chemo), atezolizumab (atezo-chemo), atezolizumab, bevacizumab (atezo-beva-chemo), single-agent pembrolizumab, and...
This study aimed to estimate the utility values of all subtypes lung cancer. The trajectories after different kinds treatments and their major determinants were explored on basis real-world data repeated measurements.From 2011 2017, patients with cancer who visited a medical center invited fill out EuroQol Five-Dimension WHO Quality Life-Brief questionnaires at each visit. Utility quality life (QoL) diagnosis depicted using kernel smoothing method. We constructed linear mixed models predict...
This study sought to determine whether exclusionary EGFR mutation testing followed by next-generation sequencing (NGS) is a cost-efficient and timely strategy in areas with high prevalence rates of mutation.We developed decision tree model compare NGS up-front NGS. Patients entered the upon diagnosis metastatic lung adenocarcinoma. Gene alterations FDA-approved targeted therapies included EGFR, ALK, ROS1, BRAF, RET, MET, NTRK, KRAS. Model outcomes were testing-related costs; time-to-test...
LBA7511 The full, final text of this abstract will be available in Part II the 2011 Annual Meeting Proceedings, distributed onsite at on June 4, 2011, and as a supplement to 20, issue Journal Clinical Oncology.
Objectives Two oral targeted therapies, gefitinib and erlotinib, were first approved then launched into the market for treatment of late-stage non-small cell lung cancer (NSCLC) in Taiwan 2003 2006, respectively. The aim this study to determine trends burden examine changes cancer-related survival rates mortality following launch these new drugs. Setting Yearly data (1994–2013), including incidence, number newly diagnosed patients, rate mortality, retrieved from Cancer Registry Database....
Abstract Low-dose computed tomography screening can be used to diagnose lung cancer at a younger age compared no screening. Real-world studies observing mortality after diagnosis are subject lead-time bias. This study developed method using nationwide registry and stage shift from trial for the adjustment of 78,897 Taiwanese patients aged 55–82 were matched with 788,820 referents randomly selected general population ratio 1:10 by age, sex, calendar year, comorbidities, estimate pathology-...
This study attempts to quantify the difference in loss of quality-adjusted life expectancy (QALE) for patients with operable and inoperable non-small-cell lung cancer (NSCLC).A cohort consisting 1652 pathologically verified NSCLC performance status 0-1 was monitored 7 years (2005-2011) obtain survival function. further extrapolated lifetime, based on ratios between age- sex-matched referents simulated from tables National Vital Statistics Taiwan. Between 2011 2012, EuroQol 5-dimension...
Abstract Neoadjuvant immunotherapy and chemotherapy have improved the major pathological response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC). This study aimed to assess whether presence of targetable driver mutations affects efficacy combination chemotherapy. We enrolled NSCLC who received preoperative neoadjuvant therapy between January 1, 2017, December 30, 2020. was delivered platinum-doublet chemotherapy; moreover, pembrolizumab added at attending...
This study was conducted to assess the CO2-elimination efficiency of tracheal gas insufflation (TGI) in 20 patients with acute respiratory distress syndrome and compare its efficacy during volume-controlled (VCV) pressure-controlled ventilation (PCV). TGI initially applied as an adjunct VCV, continuous flows (Vcath) 4 6 L/min delivered through a catheter positioned 2 cm above carina. Total effective tidal volume (VTeff) held constant. The percent reductions PaCO2 (% delta PaCO2) were 13.3...
Abstract Background and objective Previous studies have demonstrated that positive blood culture could contribute to poorer outcomes in patients with pneumonia. However, the impact of on sepsis‐induced acute respiratory distress syndrome ( ARDS ) has not been evaluated. Methods An observational study prospectively screened 4861 admitted medical or surgical intensive care units ICU s) a tertiary referral centre was performed. Results Among patients, 146 diagnosed were enrolled (mean age: 66.1...
Three different tyrosine kinase inhibitors have been approved as first-line therapies for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer with similar overall survival. This study determined dynamic changes in quality of life (QoL) patients using these after controlling potential confounders.From 2011 to 2016, we prospectively assessed the utility values and QoL scores EuroQol five-dimension World Health Organization Quality-of-Life - Brief...
Interventions Targeted therapies have been proven to provide clinical benefits patients with metastatic non-small cell lung cancer (NSCLC). Gefitinib was initially approved and reimbursed as a third-line therapy for advanced NSCLC by the Taiwan National Health Insurance (NHI) in 2004; subsequently it became second-line (in 2007) further first-line 2011) epidermal growth factor receptor mutation-positive NSCLC. Another targeted therapy, erlotinib, 2007, 2008. Objectives This study is aimed...
Abstract Background Using broad range cell-free DNA sequencing (BRcfDNA-Seq), a nontargeted next-generation (NGS) methodology, we previously identified novel class of approximately 50 nt ultrashort single-stranded (uscfDNA) in plasma that is distinctly different from 167 bp mononucleosomal (mncfDNA). We hypothesize uscfDNA possesses characteristics are useful for disease detection. Methods BRcfDNA-Seq, examined both cfDNA populations the 18 noncancer controls and 14 patients with late-stage...
Objectives To examine whether the Global Initiative for Chronic Obstructive Pulmonary Disease ( GOLD ) 2013 revision offers greater predictive ability than body mass index, airflow obstruction, dyspnea, and exacerbations BODE x) index in elderly adults with chronic obstructive pulmonary disease COPD ). Design Prospective cohort study. Setting University‐affiliated medical center. Participants Taiwanese outpatients (N = 354). Measurements were classified as Group A (low risk mild dyspnea), B...